Medtronic (NYSE:MDT) announced on Tuesday that the U.S. FDA cleared its SmartGuard algorithm as an interoperable automated ...

The company received FDA authorization to pair its 780G insulin pump with a glucose sensor made by Abbott, and to use the ...

Medtronic has obtained a pair of major green lights from the FDA for its flagship insulin pump—opening up the MiniMed 780G to adults with type 2 diabetes in the U.S., and allowing it to c | ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden the MiniMed™ 780G system portfolio: ...

Medtronic has received clearance for its SmartGuard algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with Abbott’s Instinct sensor for Type ...

Abbott will supply Medtronic with a CGM that will work exclusively with Medtronic smart dosing devices and software across both automated insulin delivery and smart multiple daily injections systems.

New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved PR Newswire GALWAY, Ireland, April 18, 2025 Latest approval expands Medtronic CGM portfolio in the U.S.

The CE Mark allows this next-generation sensor to be integrated with either the MiniMed™ 780G insulin pump system or InPen, or for stand-alone continuous glucose monitoring (CGM) use.

The Guardian Connect system leverages the Guardian™ Sensor 3, the most advanced glucose sensor from Medtronic, to accurately alert users of lows more than 90% of the time,2 so users can feel ...

With the FDA approval of a new continuous glucose monitoring system with machine learning capabilities to predict highs and lows in blood-glucose levels, Medtronic makes a bigger play for type 2 ...

Medtronic estimates the CGM sensor market to be worth $1 billion and expects it to grow to $2 billion though there are other reports that describe a much bigger market.